Verapamil and its derivative trigger apoptosis through glutathione extrusion by multidrug resistance protein MRP1

Cancer Research

Volumn 64, Issue 14, 2004, Pages 4950-4956

  Trompier, Doriane ^a   Chang, Xiu Bao ^b   Barattin, Régis ^c   Du Moulinet D'Hardemare, Amaury ^c   Di Pietro, Attilio ^a   Baubichon Cortay, Hélène ^a  

^a INSTITUT DE BIOLOGIE ET CHIMIE DES PROTÉINES   (France)

^b MAYO CLINIC   (United States)

^c UNIVERSITÉ JOSEPH FOURIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE INHIBITOR; FLUORESCEIN; GLUTATHIONE; LEUKOTRIENE C4; LIPOCORTIN 5; MULTIDRUG RESISTANCE PROTEIN 1; MUTANT PROTEIN; VERAPAMIL; VERAPAMIL DERIVATIVE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL STRAIN BHK; CONTROLLED STUDY; DRUG MECHANISM; DRUG SELECTIVITY; FLUORESCENCE; GENETIC TRANSFECTION; IN VITRO STUDY; MEMBRANE TRANSPORT; MEMBRANE VESICLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS; CELL LINE; CRICETINAE; GLUTATHIONE; HUMANS; LEUKOTRIENE C4; MEMBRANES; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; TRANSFECTION; VERAPAMIL;

EID: 3142711532     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0143     Document Type: Article

References (35)

1. Ling, V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 1997;40 Suppl:S3-8.
2. Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650-4.
3. Bates SE. Solving the problem of multidrug resistance: ABC transporters in clinical oncology. In: S. P. C. Cole, I. B. Holland, K. Kuchler, C. F. Higgins (eds.), ABC proteins from bacteria to man. London:Academic Press, 2003. p. 359-392.
4. Leslie EM, Deeley RG, Cole SP. Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology 2001;167:3-23.
5. Loe DW, Almquist KC, Deeley RG, Cole SP. Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J Biol Chem 1996;271:9675-82.
6. Renes J, de Vries EG, Nienhuis EF, Jansen PL, Muller M. ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br J Pharmacol 1999;126:681-8.
7. Wijnholds J, Evers R, van Leusden MR, et al. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat Med 1997;3:1275-9.
8. Leslie EM, Mao Q, Oleschuk CJ, Deeley RG, Cole SP. Modulation of multidrug resistance protein 1 (MRP1/ABCC1) transport and atpase activities by interaction with dietary flavonoids. Mol Pharmacol 2001;59:1171-80.
9. Trompier D, Baubichon-Cortay H, Chang XB, et al. Multiple flavonoid-binding sites within multidrug resistance protein MRP1. Cell Mol Life Sci 2003;60:2164-77.
10. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981;41:1967-72.
11. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Potentiation of vincristine and Adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors. Cancer Res 1983;43:2267-72.
12. Tsuruo T, Iida H, Nojiri M, Tsukagoshi S, Sakurai Y. Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res 1983;43:2905-10.
13. Huet S, Robert J. The reversal of doxorubicin resistance by verapamil is not due to an effect on calcium channels. Int J Cancer 1988;41:283-6.
14. Cole SP, Sparks KE, Fraser K, et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 1994;54:5902-10.
15. Davey RA, Longhurst TJ, Davey MW, et al. Drug resistance mechanisms and MRP expression in response to epirubicin treatment in a human leukaemia cell line. Leuk Res 1995;19:275-82.
16. Loe DW, Deeley RG, Cole SP. Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res 1998;58:5130-6.
17. Loe DW, Deeley RG, Cole SP. Verapamil stimulates glutathione transport by the 190-kDa multidrug resistance protein 1 (MRP1). J Pharmacol Exp Ther 2000;293: 530-8.
18. Cullen KV, Davey RA, Davey MW. Verapamil-stimulated glutathione transport by the multidrug resistance-associated protein (MRP1) in leukaemia cells. Biochem Pharmacol 2001;62:417-24.
19. Dalton WS, Grogan TM, Meltzer PS, et al. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1989;7:415-24.
20. Hou Y, Cui L, Riordan JR, Chang X. Allosteric interactions between the two non-equivalent nucleotide binding domains of multdrug resistance protein MRP1. J Biol Chem 2000;275:20280-7.
21. Chang XB, Hou YX, Riordan JR. ATPase activity of purified multidrug resistance-associated protein. J Biol Chem 1997;272:30962-8.
22. Leslie EM, Deeley RG, Cole SP. Bioflavonoid stimulation of glutathione transport by the 190-kDa multidrug resistance protein 1 (MRP1). Drug Metal Dispos 2003;31:11-5.
23. Teodori E, Dei S, Quidu P, et al. Design, synthesis, and in vitro activity of catamphiphilic reverters of multidrug resistance: discovery of a selective, highly efficacious chemosensitizer with potency in the nanomolar range. J Med Chem 1999;42:1687-97.
24. Bois F, Beney C, Boumendjel A, Mariotte AM, Conseil G, Di Pietro A. Halogenated chalcones with high-affinity binding to P-glycoprotein: potential modulators of multidrug resistance. J Med Chem 1998;41:4161-4.
25. Loe DW, Oleschuk CJ, Deeley RG, Cole SP. Structure-activity studies of verapamil analogs that modulate transport of leukotriene C(4) and reduced glutathione by multidrug resistance protein MRP1. Biochem Biophys Res Commun 2000;275:795-803.
26. Ghibelli L, Coppola S, Rotilio G, Lafavia E, Maresca V, Ciriolo MR. Non-oxidative loss of glutathione in apoptosis via GSH extrusion. Biochem Biophys Res Commun 1995;216:313-20.
27. van den Dobbelsteen DJ, Nobel CS, Schlegel J, Cotgreave IA, Orrenius S, Slater AF, Rapid and specific efflux of reduced glutathione during apoptosis induced by anti-Fas/APO-1 antibody. J Biol Chem 1996;271:15420-7.
28. Pullar JM, Hampton MB. Diphenyleneiodonium triggers the efflux of glutathione from cultured cells. J Biol Chem 2002;277:19402-7.
29. Ghibelli L, Fanelli C, Rotilio G, et alRescue of cells from apoptosis by inhibition of active GSH extrusion. FASEB J 1998;12:479-86.
30. Ghibelli L, Coppola S, Fanelli C, et al. Glutathione depletion causes cytochrome c release even in the absence of cell commitment to apoptosis. FASEB J 1999;13:2031-6.
31. Grech KV, Davey RA, Davey MW. The relationship between modulation of MDR and glutathione in MRP-overexpressing human leukemia cells. Biochem Pharmacol 1998;55:1283-9.
32. He YY, Huang JL, Ramirez DC, Chignell CF. Role of reduced glutathione efflux in apoptosis of immortalized human keratinocytes induced by UVA. J Chem 2003;278:8058-64.
33. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000;21:485-95.
34. Lehne G, De Angelis P, den Boer M, Rugstad HE. Growth inhibition, cytokinesis failure and apoptosis of multidrug-resistant leukemia cells after treatment with P-glycoprotein inhibitory agents. Leukemia 1999;13:768-78.
35. Karwatsky J, Lincoln MC, Georges E. A mechanism for P-glycoprotein- mediated apoptosis as revealed by verapamil hypersensitivity. Biochemistry 2003;42:12163-73.